Compare SUNS & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SUNS | CRBP |
|---|---|---|
| Founded | 2023 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.3M | 147.4M |
| IPO Year | N/A | 2014 |
| Metric | SUNS | CRBP |
|---|---|---|
| Price | $7.87 | $10.68 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 5 |
| Target Price | $8.75 | ★ $45.60 |
| AVG Volume (30 Days) | 116.1K | ★ 226.8K |
| Earning Date | 05-14-2026 | 05-08-2026 |
| Dividend Yield | ★ 15.31% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $4,822,272.00 |
| Revenue This Year | $70.81 | N/A |
| Revenue Next Year | N/A | $116.00 |
| P/E Ratio | $8.84 | ★ N/A |
| Revenue Growth | N/A | ★ 97.62 |
| 52 Week Low | $7.46 | $6.10 |
| 52 Week High | $11.78 | $20.56 |
| Indicator | SUNS | CRBP |
|---|---|---|
| Relative Strength Index (RSI) | 41.11 | 63.28 |
| Support Level | $7.46 | $7.91 |
| Resistance Level | $10.27 | $11.64 |
| Average True Range (ATR) | 0.22 | 0.71 |
| MACD | 0.05 | 0.06 |
| Stochastic Oscillator | 58.73 | 85.59 |
Sunrise Realty Trust Inc is a real estate investment trust company. It is focus on originating CRE debt investments and providing capital to high-quality borrowers and sponsors with transitional business plans collateralized by CRE assets with opportunities for near-term value creation, as well as recapitalization opportunities. It intends to create a diversified investment portfolio, targeting investments in senior mortgage loans, mezzanine loans, whole loans, B-notes, CMBS and debt-like preferred equity securities across CRE asset classes and investment mix to include high quality multi-family, condominiums, retail, office, hospitality, industrial, mixed use and specialty-use real estate.
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.